The burgeoning field of bioelectronic medicine has been buzzing recently with Google affiliate Verily (previously Google Life Sciences) and medical company GlaxoSmithKline joining forces in a $715 million deal to launch Galvani Bioelectronics. By tapping into our bodies’ natural electrical signals, these tiny, implantable devices have the potential to support a new class of therapies known as “electroceuticals.”